公开(公告)号：US20240410009A1

公开(公告)日：2024-12-12

申请号：US18815555

申请日：2024-08-26

Applicant: GENENTECH, INC.

Inventor： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC: C12Q1/6883 ,  A61K39/00 ,  A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  G01N33/564

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

公开(公告)号：US20220098668A1

公开(公告)日：2022-03-31

申请号：US17553210

申请日：2021-12-16

Applicant: GENENTECH, INC.

Inventor： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC: C12Q1/6883 ,  G01N33/564 ,  A61K39/395 ,  C07K16/28 ,  C07K16/24

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

公开(公告)号：US12098426B2

公开(公告)日：2024-09-24

申请号：US17553210

申请日：2021-12-16

Applicant: GENENTECH, INC.

Inventor： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC: A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  C12Q1/6883 ,  G01N33/564 ,  A61K39/00

CPC classification number: C12Q1/6883 ,  A61K39/3955 ,  C07K16/244 ,  C07K16/2866 ,  G01N33/564 ,  A61K2039/505 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/47 ,  G01N2333/522 ,  G01N2333/535 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/8146 ,  G01N2800/285 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

公开(公告)号：US11236391B2

公开(公告)日：2022-02-01

申请号：US15662079

申请日：2017-07-27

Applicant: Genentech, Inc.

Inventor： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC: A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  C12Q1/6883 ,  G01N33/564 ,  A61K39/00

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.